State Street’s Impact BioMedical IBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273K Buy
48,711
+542
+1% +$3.17K ﹤0.01% 3817
2026
Q2
$280K Hold
48,169
– – ﹤0.01% 3803
2026
Q1
$365K Buy
48,169
+47,234
+5,052% +$298K ﹤0.01% 3731
2025
Q4
$5.96K Hold
935
– – ﹤0.01% 4280
2025
Q3
$7.84K Hold
935
– – ﹤0.01% 4273
2025
Q2
$7.64K Hold
935
– – ﹤0.01% 4247
2025
Q1
$10.3K Buy
935
+50
+6% +$1.09K ﹤0.01% 4252
2024
Q4
$16.2K Buy
+885
New +$23.2K ﹤0.01% 4250

Other funds holding IBO

State Street's IBO Position: Q3 2026 in Review

State Street increased its Impact BioMedical (IBO) stake by 1.1% in Q3 2026, buying an estimated $3.17K and bringing the position to 48,711 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

State Street first reported a position in IBO in Q4 2024 and has held it in 8 quarters since. The position peaked at $365K in Q1 2026. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

  • State Street held 48,711 shares of Impact BioMedical worth $273K as of Q3 2026.
  • State Street bought 542 Impact BioMedical shares in Q3 2026, an estimated $3.17K.
  • Impact BioMedical made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3817 holding.
  • State Street first reported a position in Impact BioMedical in Q4 2024 and has held it in 8 quarters since.
  • State Street's Impact BioMedical position peaked at $365K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.